Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 [Seeking Alpha]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Seeking Alpha
Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Phase 3 lonvo-z HAE data readout, both with significant valuation impact. Lonvo-z offers potential for a one-time, functional cure in HAE, with strong efficacy and a manageable safety profile, but market adoption hinges on Phase 3 results. NTLA faces binary risk: success could unlock multi-billion-dollar markets, while safety or regulatory setbacks may erase hundreds of millions in market cap. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » master1305/iStock via Getty Images Investment Overview - Understanding Gene Therapies Risk/Reward In my last note on Intellia Therapeutics ( NTLA ) for Seeking Alpha, at the beginning of December last year, I downgraded my rating on the gene therapy specialist's stock More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal [Yahoo! Finance]Yahoo! Finance
- NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.MarketBeat
- Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 2/3/26 - Form SCHEDULE
- 1/30/26 - Form SCHEDULE
- 1/27/26 - Form 8-K
- NTLA's page on the SEC website